Therapeutic area intelligence for Neovascular Age-Related Macular Degeneration with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

EYE201 →

Recent signals(2)

ClinicalJuly 6, 2026

EYE201/MK-8748 Trial Initiated for Neovascular AMD Treatment Comparison

A clinical trial is underway to evaluate the efficacy of tiespectus (MK-8748) compared to aflibercept in treating neovascular age-related macular degeneration.

CompetitiveJuly 6, 2026

Outlook Therapeutics initiates trial for ONS-5010 in Neovascular AMD

Outlook Therapeutics is conducting a multicenter, randomized trial to evaluate the safety and effectiveness of ONS-5010 in patients with neovascular AMD.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.